| Literature DB >> 28940845 |
Maria Mytilinaiou1, Dragana Nikitovic1, Aikaterini Berdiaki1, Antonis Kostouras1, Antonis Papoutsidakis1, Aristidis M Tsatsakis2, George N Tzanakakis1.
Abstract
Syndecan 2 (SDC2) belongs to a four-member family of evolutionary conserved small type I transmembrane proteoglycans consisting of a protein core to which glycosaminoglycan chains are covalently attached. SDC2 is a cell surface heparan sulfate proteoglycan, which is increasingly drawing attention for its distinct characteristics and its participation in numerous cell functions, including those related to carcinogenesis. Increasing evidence suggests that the role of SDC2 in cancer pathogenesis is dependent on cancer tissue origin rendering its use as a biomarker/therapeutic target feasible. This mini review discusses the mechanisms, through which SDC2, in a distinct manner, modulates complex signalling networks to affect cancer progression.Entities:
Keywords: cancer biology; glycobiology; proteoglycans; syndecan
Mesh:
Substances:
Year: 2017 PMID: 28940845 DOI: 10.1002/iub.1678
Source DB: PubMed Journal: IUBMB Life ISSN: 1521-6543 Impact factor: 3.885